logo
  

Patterson-UTI Energy Posts Q2 Loss - Quick Facts

Patterson-UTI Energy Inc. (PTEN) reported a net loss of $19.0 million, or $0.13 per share, for the second quarter of 2015, compared to net income of $54.3 million, or $0.37 per share, prior year. The company noted that its financial results for the quarter ended June 30, 2015 include a pretax non-cash impairment charge of $4.1 million related to the impairment of certain oil and natural gas properties.

On average, 29 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.27 for the quarter. Analysts' estimates typically exclude special items.

Revenues were $473 million, compared to $757 million for the second quarter of 2014. Analysts expected revenue of $439.77 million for the quarter.

Andy Hendricks, Patterson-UTI's CEO, stated, "Market conditions were difficult during the second quarter as the rapid decline in the industry rig count created many challenges."

The company declared a quarterly dividend on its common stock of $0.10 per share, to be paid on September 24, 2015 to holders of record as of September 10, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT